Skip to main content

Table 3 Characteristics of OPCRD patients with COPD that fulfil study criteria in Table 1 (n = 36 893)

From: Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy

Characteristic

Age, mean (SD)

71.3 (10.6)

Male, n (%)

19 478 (52.8)

FEV1 % predicted, mean (SD)

62.5 (20.0)

GOLD category of airflow limitation, n (%)

 GOLD 1: FEV1 ≥ 80 %

19.3 % (7 118)

 GOLD 2: 50 % ≤ FEV1 < 80 %

53.5 % (19 755)

 GOLD 3: 30 % ≤ FEV1 < 50 %

23.0 % (8 468)

 GOLD 4: FEV1 < 30 %

4.2 % (1 552)

mMRC score grade ≥2, n (%)

17 075 (46.3)

Pack years of smoking, n (%):

  ≥ 10

34 758 (94.2)

  ≥ 20

34 232 (92.8)

Maintenance therapya prescribed within 6 months, n (%)

25 594 (69.4)

Symptomaticb, n (%)

29 579 (80.2)

History of ≥ 1 exacerbation in the last year, n (%)

18 373 (49.8)

  1. Abbreviations: COPD chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung Disease [2], ICS inhaled corticosteroids, LABA long-acting β-agonists, LAMA long-acting muscarinic antagonists, LTRA leukotriene receptor antagonists, mMRC score modified Medical Research Council score [2]
  2. aICS, LAMA, LABA, LTRA or phosphodiesterase inhibitors
  3. bmMRC grade ≥2, or maintenance therapy prescribed within 6 months